journal article·2017-11-17

Silibinin-loaded magnetic nanoparticles inhibit hTERT gene expression and proliferation of lung cancer cells

Soumaye Amirsaadat, Younes Pilehvar-Soltanahmadi, Faraz Zarghami, Shahriar Alipour, Zohreh Ebrahimnezhad, Nosratollah Zarghami

Publisher page

Abstract

Nanoparticle-based targeted drug delivery has the potential for rendering silibinin specifically at the favorite site using an external magnetic field. Also, it can circumvent the pitfalls of poor solubility. For this purpose, silibinin-loaded magnetic nanoparticles are fabricated, characterized and evaluated cytotoxicity and hTERT gene expression in A549 lung cancer cell line. silibinin-loaded PLGA-PEG-Fe3O4 had dose- and time-dependent cytotoxicity than pure silibinin. Additionally, hTERT expression is more efficiently reduced with increasing concentrations of nanosilibinin than pure silibinin. The present study indicates that PLGA-PEG-Fe3O4 nanoparticles, as an effective targeted carrier, can make a promising horizon in targeted lung cancer therapy.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Silymarin and Mushroom Poisoning · Trace Elements in Health · Peptidase Inhibition and Analysis

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Medical Biotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran;

Molecular Medicine, Faculty of Advanced Medical Sciences, Tabriz university of Medical Sciences, Iran

References (33)

Show source-provided references
1. 10.7314/APJCP.2014.15.20.893110.7314/APJCP.2014.15.20.8931 ↗
2. 10.2174/092986732366616042511370510.2174/0929867323666160425113705 ↗
3. Ardebili MO · SSU_J · 2015 · 23 · 2000
4. 10.1016/S0168-3659(01)00530-210.1016/S0168-3659(01)00530-2 ↗
5. 10.1016/j.ijpharm.2005.03.02410.1016/j.ijpharm.2005.03.024 ↗
6. Bodnar A · Nat Genet · 1997 · 17 · 502
7. 10.1021/jp077468+10.1021/jp077468+ ↗
8. 10.1007/s10555-010-9237-010.1007/s10555-010-9237-0 ↗
9. 10.1002/ddr.2006710.1002/ddr.20067 ↗
10. 10.3109/0363904090332556010.3109/03639040903325560 ↗
11. Ebrahimnezhad Z · Bioimpacts · 2013 · 3 · 67
12. 10.1002/ijc.2921010.1002/ijc.29210 ↗
13. Kazemi-Lomedasht F · Adv Pharm Bull · 2013 · 3 · 127
14. 10.1097/00002371-199705000-0000310.1097/00002371-199705000-00003 ↗
15. 10.1126/science.760542810.1126/science.7605428 ↗
16. 10.1186/2193-8865-3-6210.1186/2193-8865-3-62 ↗
17. 10.1517/14728222.2016.112123610.1517/14728222.2016.1121236 ↗
18. 10.1016/S0168-3659(01)00218-810.1016/S0168-3659(01)00218-8 ↗
19. 10.1158/1535-7163.MCT-13-094210.1158/1535-7163.MCT-13-0942 ↗
20. Mateen S · Mol Carcinog · 2010 · 49 · 58
21. 10.7314/APJCP.2014.15.20.869310.7314/APJCP.2014.15.20.8693 ↗
22. 10.17795/ijcp-419010.17795/ijcp-4190 ↗
23. 10.7314/APJCP.2015.16.18.825910.7314/APJCP.2015.16.18.8259 ↗
24. 10.3109/21691401.2015.112961510.3109/21691401.2015.1129615 ↗
25. 10.1007/s10616-012-9452-310.1007/s10616-012-9452-3 ↗
26. 10.3144/expresspolymlett.2016.3410.3144/expresspolymlett.2016.34 ↗
27. 10.1016/j.ijbiomac.2014.05.03510.1016/j.ijbiomac.2014.05.035 ↗
28. 10.1016/S0959-8049(97)00062-210.1016/S0959-8049(97)00062-2 ↗
29. 10.3322/caac.2013810.3322/caac.20138 ↗
30. 10.1093/jnci/djj23110.1093/jnci/djj231 ↗
31. 10.1006/phrs.2001.085410.1006/phrs.2001.0854 ↗
32. 10.1038/aps.2016.2010.1038/aps.2016.20 ↗
33. 10.3390/antiox401020410.3390/antiox4010204 ↗